English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduMD Anderson and CureVac today announced a co-development and licensing agreement to develop novel mRNA-based cancer vaccines.
Tag: mRNA vaccine
Pure capped mRNA vaccine opens the door to more effective vaccines with lower chances of inflammation
A research group from Japan has developed a method to produce highly active mRNA vaccines at high purity using a unique cap to easily separate the desired capped mRNA.
Hypertension Elevates Risk for More Severe COVID-19 Illness
Hypertension more than doubles the risk of hospitalization related to Omicron infection, even in people who are fully vaccinated and boosted, according to a new study led by investigators in the Smidt Heart Institute at Cedars-Sinai. The findings are published in the journal Hypertension.
University of Pennsylvania’s First NFT Commemorates mRNA Research
The historic scientific breakthrough at the Perelman School of Medicine at the University of Pennsylvania that helped lead the world’s fight against COVID-19 through mRNA-based vaccines is being commemorated through a non-fungible token—a digital asset to be auctioned by Christie’s—that will support ongoing research at Penn.
World-first COVID vaccine booster randomized clinical trial in transplant patients proves third shot is very effective
The study enrolled 120 transplant patients between May 25th and June 3rd. None of them had COVID previously and all of them had received two doses of the Moderna vaccine. Half of the participants received a third shot of the vaccine (at the 2-month mark after their second dose) and the other half received placebo.
The primary outcome was based on antibody level greater than 100 U/ml against the spike protein of the virus. In the placebo group – after three doses (where the third dose was placebo), the response rate was only 18% whereas in the Moderna three-dose group, the response rate was 55%.
World-first COVID vaccine booster randomized clinical trial in transplant patients proves third shot is very effective
The study enrolled 120 transplant patients between May 25th and June 3rd. None of them had COVID previously and all of them had received two doses of the Moderna vaccine. Half of the participants received a third shot of the vaccine (at the 2-month mark after their second dose) and the other half received placebo. The primary outcome was based on antibody level greater than 100 U/ml against the spike protein of the virus. In the placebo group – after three doses (where the third dose was placebo), the response rate was only 18% whereas in the Moderna three-dose group, the response rate was 55%.
Had COVID-19? One vaccine dose enough; boosters for all, study says
A new study in ACS Nano supports increasing evidence that people who had COVID-19 need only one vaccine dose, and that boosters could be necessary for everyone in the future.
Low on Antibodies, Blood Cancer Patients Can Fight off COVID-19 with T Cells
Antibodies aren’t the only immune cells needed to fight off COVID-19 — T cells are equally important and can step up to do the job when antibodies are depleted, suggests a new Penn Medicine study of blood cancer patients with COVID-19 published in Nature Medicine.
Messenger RNA COVID-19 vaccines greatly reduce risk of asymptomatic COVID-19 infection, spread to others
Ten days after receiving a second dose of a messenger RNA, or mRNA, vaccine for COVID-19, patients without COVID-19 symptoms are far less likely to test positive and unknowingly spread COVID-19, compared to patients who have not been vaccinated for COVID-19. The Pfizer-BioNTech and Moderna messenger RNA vaccines for COVID-19 are authorized for emergency use in the U.S.
An mRNA vaccine for cancer immunotherapy
Researchers reporting in ACS’ Nano Letters have developed a hydrogel that, when injected into mice with melanoma, slowly released RNA nanovaccines that shrank tumors and kept them from metastasizing.